A Phase I Clinical Trial of an HPV Therapeutic Vaccine
This study will consist of 300 women aged 18-50 years. The study will show that a new therapeutic human papillomavirus (HPV) vaccine designed to regress a precancerous condition called high-grade squamous intraepithelial neoplasia (HSIL)is safe. HPV is known to cause cervical, vaginal, oral, and anal cancers. This novel vaccine will consist of a synthetically made fragment of HPV protein called E6 and yeast extract called Candin®. Previous studies have revealed that immune response to E6 is important in fighting HPV. We also know that injecting Candin has anti-HPV effect since it has been used to treat common warts which are caused by different types of HPV. The current standard treatment for HSIL is loop electrical excision procedure (LEEP). The immune system is the part of the body that fights infection and cancer. This research study will also examine the immune response to the vaccine and its effectiveness in regressing HSIL. Volunteers would be eligible to enroll in the study if they have had a recent Papanicolaou (Pap) smear result indicating HSIL or "Cannot rule out HSIL", and if they meet the inclusion/exclusion criteria. Subjects will be eligible to receive vaccinations if biopsy confirms HSIL. A series of four vaccinations will be given roughly 3 weeks apart, and LEEP will be performed at the end of the study approximately 12 weeks after the last vaccination.
Biological: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||A Phase I Clinical Trial of an HPV Therapeutic Vaccine|
- safety [ Time Frame: immediately then up to 7 days post vaccinations ] [ Designated as safety issue: Yes ]real-time safety measurement of the combined administration of HPV vaccine and Candin® as measured by dose limiting toxicity as defined by adverse events; safety will be assessed at time of vaccination, 30 minutes post-injection, and daily for 7 days post injections.
- clinical and virological/immunological response to the HPV vaccine [ Time Frame: within weeks of vaccinations or procedures ] [ Designated as safety issue: No ]Clinical response as defined by loop electrical excision procedure (LEEP); virological assessment to assess the clearance of HPV infection after vaccination; immunological assessments of T-Cells and circulating immune cells (regulated T-Cells and myeloid derived suppressor cells); and assessment of cervical immune cells.
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
|Biological: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01653249
|Contact: Shawna S Owens, BSB, CCRPfirstname.lastname@example.org|
|United States, Arkansas|
|University of Arkansas for Medical Sciences||Recruiting|
|Little Rock, Arkansas, United States, 72205|
|Contact: Shawna S Owens, BSB, CCRP 501-526-7657 email@example.com|
|Principal Investigator: Mayumi Nakagawa, MD, PhD|
|Principal Investigator:||Mayumi Nakagawa, MD, PhD||University of Arkansas|
|Principal Investigator:||William W Greenfield, MD||University of Arkansas|